SGLT2 inhibitors improve renal outcomes in people with chronic kidney disease independent of the presence of diabetes.2, 3, 4, 5, 6, 7 The most likely explanation of this renal benefit is that SGLT2 inhibitors reduce intraglomerular pressure due to activation of tubuloglomerular feedback secondary to increased sodium and chloride delivery to the macula densa.8 Here, SLC5A2 is linked to chronic kidney disease.